Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News


Novartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse


As San­doz returns mar­ket­ing rights for dig­i­tal ther­a­peu­tics to Pear, what does it mean for co-pro­mote arrange­ments? (MM&M):

San­doz, the gener­ics divi­sion of Novar­tis, is alter­ing com­mer­cial course, return­ing mar­ket­ing duties for two pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) back to Pear Ther­a­peu­tics. The move, which some had antic­i­pat­ed, comes 18 months after the two signed a co-pro­mo­tion deal.

Since the Sandoz/Pear pact was wide­ly seen as a lit­mus test of sorts for pharma’s role in help­ing dis­trib­ute this nascent tech­nol­o­gy, the com­mer­cial break-up rais­es ques­tions about the via­bil­i­ty of such part­ner­ships going for­ward. It also high­lights the par­ties’ some­times con­flict­ing pri­or­i­ties: pharma’s con­cern about its core busi­ness ver­sus dig­i­tal ther­a­peu­tics firms’ wor­ries about fund­ing and invest­ment…

Despite the Sandoz/Pear news, he and oth­ers fore­see such col­lab­o­ra­tions con­tin­u­ing. DTx still rep­re­sents a “huge oppor­tu­ni­ty” for phar­ma, wrote Alessio Brunel­lo, senior phar­ma ana­lyst with Glob­al­Da­ta, in a note Thurs­day. DTx, he said, should see con­tin­ued part­ner­ship activ­i­ty in R&D and ther­a­peu­tics, due in part to pres­sure on health sys­tems from the aging pop­u­la­tion and increas­ing costs and in part to the poten­tial of improved adher­ence.

DTx can be pre­scribed as monother­a­py or togeth­er with oth­er ther­a­pies to pre­vent, man­age or treat dis­eases across diverse indi­ca­tions, par­tic­u­lar­ly chron­ic dis­eases and neu­ro­log­i­cal dis­or­ders. Pear’s reSET prod­uct, approved by the FDA in 2017, was the first soft­ware appli­ca­tion sanc­tioned for clin­i­cal use to treat sub­stance use dis­or­der (SUD) relat­ed to stim­u­lants, cannabis, cocaine and alco­hol…

Pay­ers think of these solu­tions as dif­fer­ent, she (Lisa Flaiz at Bris­tol-Myers Squibb) said. “But in my opin­ion, it shouldn’t mat­ter whether it’s a pill or an app. If the out­comes are the same, the pay­ers should be pay­ing for the out­come.”

News in Context:

Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Cognitive Neuroscience, Health & Wellness, Professional Development, Technology

Tags: , , , , , , , , , ,

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters,  SharpBrains is an independent market research firm tracking how brain science can improve our health and our lives.

Search in our archives

Follow us and Engage via…

RSS Feed

Watch All Recordings Now (40+ Speakers, 12+ Hours)